Eli Lilly

Business & Economy
8:05 am
Thu April 24, 2014

GlaxoSmithKline, Novartis, Lilly Part Of Drug Asset Swap

GSK Scientist. The company says much of its focus is on respiratory therapy and HIV drugs in RTP.
Credit www.gsk.com

Big changes and asset swaps in the pharmaceutical world are happening this week, but the Triangle should be spared of any fall-out.

One of the big moves in this chess game includes Switzerland-based Novartis agreeing to spend up to $16 billion for GlaxoSmithKline’s cancer drug business in Pennsylvania.

Read more